(Q45268076)

English

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial

scientific article published on 7 February 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

metabolic syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Sotiris Tsiodras

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Christos Socrates Mantzoros

9

object named as

Christos S Mantzoros

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

Alina Gavrila

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

William Hsu

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

John Doweiko

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Shiva Gautam

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Lizabeth Martin

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Alan C Moses

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Adolf W Karchmer

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

7 February 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

745-749

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

Thiazolidinediones and blood lipids in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity

1 reference

https://api.crossref.org/works/10.1086%2F427697

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45268076&oldid=2072222436"